ADMA Biologics, Inc. (ADMA)
| Market Cap | 1.52B |
| Revenue (ttm) | 258.22M |
| Net Income (ttm) | -28.24M |
| Shares Out | 231.77M |
| EPS (ttm) | -0.13 |
| PE Ratio | n/a |
| Forward PE | 20.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,536,662 |
| Open | 6.47 |
| Previous Close | 6.44 |
| Day's Range | 6.40 - 6.60 |
| 52-Week Range | 3.06 - 6.76 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 7.88 (+20.31%) |
| Earnings Date | May 8, 2024 |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other liste... [Read more]
Financial Performance
In 2023, ADMA Biologics's revenue was $258.22 million, an increase of 67.59% compared to the previous year's $154.08 million. Losses were -$28.24 million, -57.15% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ADMA stock is "Strong Buy." The 12-month stock price forecast is $7.88, which is an increase of 20.31% from the latest price.
News
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to man...
ADMA Biologics Announces CFO Transition
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA ( 1) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income ( 2...
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes ADMA Successfully Utilized ADMAlytics' New Capabilities for the First Time to Automate and Realize Efficiency Im...
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Millio...
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt Further Supports Rapid Q-o-Q and Y-o-Y Earnings Accretion RAMSEY, N.J. and BOCA RATON, Fla...
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
Signifies the Successful Fulfillment of BIVIGAM's Post Marketing Commitments as Part of the Original BLA Approval
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
FDA Approval Signifies the Accomplishment of ADMA's Corporate Goal of Plasma Supply Self-Sufficiency FDA Approval Signifies the Accomplishment of ADMA's Corporate Goal of Plasma Supply Self-Sufficienc...
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million First-Time Positive Operating Cash Flow of $12.0 Million, Growing Total Cash Balance to...
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA (1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss (2) of $3.6 Million, a 74% Y-o-Y Improvement ...
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY...
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update
1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1) , Totaling $2.5 Million,...
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces Amendment to Credit Agreement
Reduces Nominal Interest Rate by 1% Provides for Improved Prepayment Flexibility Total Debt Level Unchanged Favorable Amendment Enabled by Strengthened Financial Outlook RAMSEY, N.J. and BOCA RATON, F...
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase
ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance
Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®
FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manuf...
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manuf...